Notably, PTC596 in combination with bortezomib also induced significant cytotoxicity in primary CD138+ cells from the BM of patients with MM compared with bortezomib alone, as evidenced by reductions in Annexin V-negative viable cells (Fig. 3D). This evidence concerns the gene SDC1 and Miyoshi myopathy.